Cadmus Rich - Jan 19, 2023 Form 4 Insider Report for Aura Biosciences, Inc. (AURA)

Role
Chief Medical Officer, Head of R&D
Signature
/s/ Julie Feder, as Attorney-in-Fact
Stock symbol
AURA
Transactions as of
Jan 19, 2023
Transactions value $
$0
Form type
4
Date filed
1/23/2023, 05:34 PM
Previous filing
Nov 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AURA Common Stock Award $0 +34.1K +138.84% $0.00 58.7K Jan 19, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AURA Stock Option (Right to Buy) Award +52.5K 52.5K Jan 19, 2023 Common Stock 52.5K $10.18 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on the one year anniversary of the date of grant.
F2 The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of January 19, 2023 with the remainder vesting thereafter pro-rata in 36 monthly installments.

Remarks:

Chief Medical Officer, Head of R&D